{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:45:39Z","timestamp":1774770339101,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Keymed Biosciences (Chengdu) Co.,Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40259-025-00714-4","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T17:45:04Z","timestamp":1743875104000},"page":"487-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct04842201","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05171348","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05715333","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yujing","family":"Di","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyue","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"1","key":"714_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2023","unstructured":"Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24\u201337.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"714_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.4049\/jimmunol.1100355","volume":"187","author":"M Kashyap","year":"2011","unstructured":"Kashyap M, et al. Thymic stromal lymphopoietin is produced by dendritic cells. J Immunol. 2011;187(3):1207\u201311.","journal-title":"J Immunol"},{"issue":"4","key":"714_CR3","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1172\/JCI124606","volume":"129","author":"F Roan","year":"2019","unstructured":"Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest. 2019;129(4):1441\u201351.","journal-title":"J Clin Invest"},{"issue":"7","key":"714_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ni805","volume":"3","author":"V Soumelis","year":"2002","unstructured":"Soumelis V, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673\u201380.","journal-title":"Nat Immunol"},{"issue":"5","key":"714_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1084\/jem.192.5.659","volume":"192","author":"LS Park","year":"2000","unstructured":"Park LS, et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med. 2000;192(5):659\u201370.","journal-title":"J Exp Med"},{"key":"714_CR6","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.1038\/ncomms14937","volume":"8","author":"K Verstraete","year":"2017","unstructured":"Verstraete K, et al. Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun. 2017;8:14937.","journal-title":"Nat Commun"},{"issue":"9","key":"714_CR7","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20051135","volume":"202","author":"T Ito","year":"2005","unstructured":"Ito T, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213\u201323.","journal-title":"J Exp Med"},{"issue":"2","key":"714_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/rr42","volume":"2","author":"Y Zhou","year":"2001","unstructured":"Zhou Y, McLane M, Levitt RC. Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir Res. 2001;2(2):80\u20134.","journal-title":"Respir Res"},{"issue":"1","key":"714_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41577-020-0396-0","volume":"21","author":"P Angkasekwinai","year":"2021","unstructured":"Angkasekwinai P, Dong C. IL-9-producing T cells: potential players in allergy and cancer. Nat Rev Immunol. 2021;21(1):37\u201348.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"714_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12890-022-01976-2","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, et al. The absence of IL-9 reduces allergic airway inflammation by reducing ILC2, Th2 and mast cells in murine model of asthma. BMC Pulm Med. 2022;22(1):180.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"714_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/art.38338","volume":"66","author":"FM Moret","year":"2014","unstructured":"Moret FM, et al. Thymic stromal lymphopoietin, a novel proinflammatory mediator in rheumatoid arthritis that potently activates CD1c+ myeloid dendritic cells to attract and stimulate T cells. Arthritis Rheumatol. 2014;66(5):1176\u201384.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"714_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jaci.2010.03.016","volume":"125","author":"PS Gao","year":"2010","unstructured":"Gao PS, et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol. 2010;125(6):1403-1407e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"714_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.anai.2015.11.016","volume":"116","author":"IJ Wang","year":"2016","unstructured":"Wang IJ, et al. TSLP polymorphisms, allergen exposures, and the risk of atopic disorders in children. Ann Allergy Asthma Immunol. 2016;116(2):139-45e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"714_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaci.2021.05.033","volume":"149","author":"LB Murrison","year":"2022","unstructured":"Murrison LB, et al. TSLP disease-associated genetic variants combined with airway TSLP expression influence asthma risk. J Allergy Clin Immunol. 2022;149(1):79\u201388.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"714_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaci.2011.08.031","volume":"129","author":"A Shikotra","year":"2012","unstructured":"Shikotra A, et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol. 2012;129(1):104-11e1-9.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"714_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jaci.2013.04.005","volume":"132","author":"DR Nagarkar","year":"2013","unstructured":"Nagarkar DR, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593-600e12.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"714_CR17","doi-asserted-by":"publisher","first-page":"21895","DOI":"10.1038\/s41598-020-78943-6","volume":"10","author":"ML Clausen","year":"2020","unstructured":"Clausen ML, et al. Cytokine concentration across the stratum corneum in atopic dermatitis and healthy controls. Sci Rep. 2020;10(1):21895.","journal-title":"Sci Rep"},{"issue":"4","key":"714_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM. Tezepelumab: first approval. Drugs. 2022;82(4):461\u20138.","journal-title":"Drugs"},{"issue":"11","key":"714_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","volume":"9","author":"S Diver","year":"2021","unstructured":"Diver S, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299\u2013312.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"714_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936\u201346.","journal-title":"N Engl J Med"},{"key":"714_CR21","unstructured":"U.S. Food & Drug Administration. The Drug Development Process. Accessed 23 January 2025."},{"issue":"2","key":"714_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/cpt.1401","volume":"106","author":"JR Parnes","year":"2019","unstructured":"Parnes JR, et al. Pharmacokinetics, safety, and tolerability of tezepelumab (AMG 157) in healthy and atopic dermatitis adult subjects. Clin Pharmacol Ther. 2019;106(2):441\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"714_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cpdd.775","volume":"9","author":"K Sakamoto","year":"2020","unstructured":"Sakamoto K, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy Japanese men. Clin Pharmacol Drug Dev. 2020;9(7):833\u201340.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"714_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548\u201358.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00714-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:26:59Z","timestamp":1745594819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00714-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00714-4","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These studies were funded by Keymed Biosciences (Chengdu) Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bo Chen is a shareholder of Keymed Biosciences (Chengdu) Co., Ltd. Libo Zhang is an employee of Keymed Biosciences (Chengdu) Co., Ltd. Yanqiu Huang is an employee of Keymed Biosciences (Chengdu) Co., Ltd. Yingmin Jia is an employee of Keymed Biosciences (Chengdu) Co., Ltd. Hongyue Yan is an employee of Keymed Biosciences (Chengdu) Co., Ltd. Li Chen is an employee of Keymed Biosciences (Chengdu) Co., Ltd. Qiaoyun Hou is an employee of Keymed Biosciences (Chengdu) Co., Ltd. All other authors declare no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The data used and analyzed in the current studies are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability Of Data And Material"}},{"value":"These trials were conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines issued by National Medical Products Administration, and relative regulations. The protocols and amendments and other study documents, including the informed consent forms, were reviewed and approved by the ethics committee at each trial center. The HV001 trial was approved by the Drug Clinical Trial Ethics Committee of Peking University (PKU) Care, Luzhong Hospital (Beijing, China) on 27 January 2021 (approval number: [2021] No. 04) and on 26 May 2021 (approval number: [2021] No. 13). The HV002 trial was approved by the Ethics Committee on Clinical Trials, West China Hospital of Sichuan University (Chengdu, China) on 29 November 2021 and on 6 April 2022 (approval number: [2021] No. 290). The 100003 trial was approved by the Drug Clinical Trial Ethics Committee of Peking University (PKU) Care, Luzhong Hospital (Beijing, China) on 4 January 2023 (approval number: [2022] No. 50) and on 9 March 2023 (approval number: [2023] No. 08).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects provided written informed consent prior to any study procedure.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Bo Chen, Zhu Luo, and Jie Hou have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Yujing Di, Ling Yang, Jianfei Zhou, Libo Zhang, Bo Chen, Zhu Luo, Jie Hou. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: Yujing Di, Ling Yang, Jianfei Zhou, Libo Zhang. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Libo Zhang. Obtained funding: Bo Chen. Administrative, technical, or material support: Bo Chen, Zhu Luo, Jie Hou. Supervision: Bo Chen, Zhu Luo, Jie Hou.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}